Pulmonary Assessment in Thoracic Insufficiency Syndrome Patients

Sponsor
Children's Hospital of Philadelphia (Other)
Overall Status
Recruiting
CT.gov ID
NCT04977830
Collaborator
(none)
5
1
1
39
0.1

Study Details

Study Description

Brief Summary

Thoracic insufficiency syndrome (TIS) is a complex condition that involves chest wall deformities that can affect normal breathing and lung growth. In most cases, children with TIS are also born with spine disorders such as scoliosis. The inability of the thorax to support normal respiration or lung growth can cause respiratory distress and even mortality. Investigators aim to validate MRI imaging sequences to use as an assessment tool for pulmonary function.

Condition or Disease Intervention/Treatment Phase
  • Device: Xenon-129
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
5 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
New Strategies for Pulmonary Assessment in Spinal and Chest Wall Deformity
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Aug 30, 2024
Anticipated Study Completion Date :
Aug 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Other: Thoracic Insufficiency Group

Thoracic insufficiency syndrome patients undergoing surgery

Device: Xenon-129
Patients will undergo a hyperpolarized MRI with administered Xenon gas

Outcome Measures

Primary Outcome Measures

  1. Analyze volume of lungs at end-inspiration and end-expiration [up to 2 years]

    Investigators will analyze lung volume at end-inspiration and end-expiration will be assessed by performing a thoracic dynamic magnetic resonance imaging scan; measured in total volume units (mL)

  2. Xenon-129 MRI Ventilation Maps [up to 2 years]

    Xenon-129 MRI will be completed to reveal unventilated regions of the lungs where the gas cannot reach after being inhaled due to restrictions of the airways.

Secondary Outcome Measures

  1. oxygen partial pressure (PAO2) maps [up to 2 years]

    Oxygen partial pressure (PAO2) maps will be extracted from 129Xe MRI maps in a single breath-hold. Regions of the lungs that show abnormal PAO2 values are susceptible of improper ventilation or gas exchange.

  2. Forced vital capacity (FVC) [up to 2 years]

    Forced vital capacity will be extracted from the computer-automated dynamic lung MRI software.

  3. Forced expiratory volume (FEV1) [up to 2 years]

    Forced expiratory volume data will be extracted from the computer-automated dynamic lung MRI software to assess the volume of air forced from the lungs

  4. Xenon-129 MRI apparent diffusion coefficient (ADC) maps [up to 2 years]

    Apparent diffusion coefficient (ADC) maps are extracted from the Xenon-129 MRI from a single breath-hold pulse sequence.

  5. total lung capacity [up to 2 years]

    Total lung capacity will be extracted from the computer-automated dynamic lung MRI software.

  6. functional residual capacity (FRC) [up to 2 years]

    functional residual capacity data will be extracted from the computer-automated dynamic lung MRI software to measure the volume in the lungs at the end of passive expiration

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Males or females 6 to 18 years old diagnosed with thoracic insufficiency syndrome who are undergoing surgery
Exclusion Criteria:
  • patients not diagnosed with thoracic insufficiency syndrome

Contacts and Locations

Locations

Site City State Country Postal Code
1 Children's Hospital of Philadelphia Philadelphia Pennsylvania United States 19104

Sponsors and Collaborators

  • Children's Hospital of Philadelphia

Investigators

  • Principal Investigator: Patrick Cahill, MD, Children's Hopsital of Philadelphia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier:
NCT04977830
Other Study ID Numbers:
  • 20-017344
First Posted:
Jul 27, 2021
Last Update Posted:
Apr 11, 2022
Last Verified:
Apr 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Keywords provided by Children's Hospital of Philadelphia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 11, 2022